ReviewProbiotics and antimicrobial proteins2026
A Review on Functional Foods Regulate the Gut Microbiota and Mast Cell Function in Inflammatory Bowel Disease (IBD).
Review in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Inflammatory bowel disease (IBD) is a chronic condition characterised by intestinal inflammation driven by dysbiosis and immune dysfunction. Conventional therapies often have significant side effects, necessitating safer alternatives. This review explores the potential of functional foods as adjunctive therapies for IBD management. Functional foods, including prebiotics, probiotics, polyphenols, and omega-3 fatty acids, exhibit anti-inflammatory properties through various mechanisms. Prebiotics and probiotics modulate the gut microbiome, promoting the growth of beneficial bacteria and enhancing the production of anti-inflammatory metabolites. Polyphenols possess antioxidant and mast cell stabilising properties, while omega-3 fatty acids suppress pro-inflammatory cytokines. These foods can synergistically restore microbial balance, improve gut barrier function, and modulate immune responses, including reducing mast cell degranulation. Moreover, they addresses critical factors influencing their therapeutic potential, such as optimal functional food doses, bioavailability, and individual variation in response. Practical barriers to the clinical integration of functional foods, such as formulation stability, patient adherence, and regulatory constraints, are also discussed. Moreover, this review highlights the potential of dietary interventions in managing IBD by reducing reliance on medications and improving patient outcomes. However, further research is crucial to optimise the clinical application of functional foods in IBD management and to fully understand their mechanisms of action.
Indexed as
Identifiers
41014482What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.